---
title: "Descartes-08 in Generalized myasthenia gravis: Phase of product development"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Phase of product development. Topics: Summary: development and regulatory status, Regulatory status: Submission planned; BLA planned for mid-2027, Launch readiness: expanded medical affairs and commercial teams, AURORA topline data and BLA timing: first quarter of 2027 and mid-2027, and 12 further topics. 16 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Summary: development and regulatory status

- Regulatory status: The company states that it has no products approved for sale and has not generated any product sales. The FDA designated Descartes-08 an orphan drug for the treatment of myasthenia gravis on 11/08/2022 (not FDA approved for the orphan indication), and the company announced Regenerative Medicine Advanced Therapy designation for MG on May 22, 2024. A Rare Pediatric Disease Designation for juvenile dermatomyositis (JDM) was granted in September 2024; the company states that approval in JDM may qualify it for a priority review voucher.
- Special Protocol Assessment: On January 27, 2025, the company announced written agreement from the FDA under the Special Protocol Assessment process on the overall design of the phase 3 AURORA trial, which the company states the FDA determined acceptable to support a future biologics license application (BLA) in MG, subject to the outcome of the trial.
- Earlier development: The company has completed a phase 1/2 trial in MG with phase 1b, phase 2a, and phase 2b portions; phase 2a results were published in the Lancet Neurology in July 2023, phase 2b results were presented in December 2024, and 12-month data were reported in April 2025 and published in Nature Medicine in January 2026. As of December 31, 2025, Descartes-08 had been administered to over 100 patients with MG, multiple myeloma, and other diseases.
- AURORA status: The first participant was enrolled in May 2025 (registry actual study start 2025-05-06). The company describes approximately 100 participants with AChR antibody-positive MG; the registry record last updated 2026-09-01 lists actual enrollment of 128, a status of active, not recruiting, estimated primary completion on 2026-12-30, and estimated study completion on 2027-09-30. The company expects topline data in the first quarter of 2027 and plans a BLA filing in mid-2027, and states that it has expanded its medical affairs and commercial teams for launch readiness.
- Financing: Cash, cash equivalents, and restricted cash were $124.7 million as of September 30, 2026, including the initial $50 million tranche of non-dilutive financing from K2 HealthVentures and $22.8 million raised year to date through the at-the-market program; the company expects these resources to support planned operations, including completion of AURORA, into 2028. The term loan facility provides up to $150.0 million in four tranches, of which $50.0 million had been borrowed as of September 30, 2026, and requires a minimum trailing three-month net product revenue of $40.0 million beginning on January 1, 2029. The accumulated deficit was $857.3 million, and approximately $75.5 million remained available under the at-the-market program. In its full year 2025 results (2026), the company had projected that $126.9 million as of December 31, 2025, would support operations into mid-2027.
- Other indications: The phase 2 TRITON trial in moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome and the phase 1/2 HELIOS trial in children and young adults with autoimmune diseases, including JDM, are ongoing, with data from both expected in the first half of 2027. After topline data from a phase 2 trial in systemic lupus erythematosus in November 2025, the company decided to no longer pursue development in that indication.

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm); [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=909722); [Cartesian Therapeutics RMAT designation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-receives-fda-regenerative-medicine); [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456); [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm); [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment); [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled); [ClinicalTrials.gov NCT06799247](https://clinicaltrials.gov/study/NCT06799247); [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial); [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive); [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results)

<a id="topic-2.1.1-2"></a>

### Regulatory status: Submission planned; BLA planned for mid-2027

> “Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027”
> “Phase 3 AURORA Trial of Descartes-08 in Participants with MG Advances Towards Expected Data Readout in 1Q27, with BLA Planned for Mid-2027.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “We do not have any products approved for sale and have not generated any product sales.”

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)

<a id="topic-2.1.1-3"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-4"></a>

### Launch readiness: expanded medical affairs and commercial teams

> “Ahead of our anticipated BLA submission in mid-2027, we have expanded our medical affairs and commercial teams to drive launch readiness.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028.”

Source: [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)

<a id="topic-2.1.1-5"></a>

### AURORA topline data and BLA timing: first quarter of 2027 and mid-2027

> “The Company anticipates reporting topline data from the Phase 3 AURORA trial in the first quarter of 2027 with BLA filing planned for mid-2027.”

Source: [Cartesian Therapeutics K2 HealthVentures financing press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-secures-150-million-non-dilutive)

> “Cartesian remains on track to readout topline data from its Phase 3 AURORA trial of Descartes-08 in MG in the first quarter of 2027, with a BLA filing expected in mid-2027.”

Source: [Cartesian Therapeutics retreatment data press release (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-additional-retreatment-data)

<a id="topic-2.1.1-6"></a>

### Orphan Drug Designation for myasthenia gravis: designated November 2022

| Field | Quoted record |
| --- | --- |
| Generic name | “autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen” |
| Date designated | “11/08/2022” |
| Orphan designation | “Treatment of Myasthenia Gravis” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Cartesian Therapeutics, Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2022)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=909722)

<a id="topic-2.1.1-7"></a>

### Regenerative Medicine Advanced Therapy designation for myasthenia gravis: granted May 2024

> “GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Regenerative Medicine Advanced Therapy (“RMAT”) designation for Descartes-08 for the treatment of myasthenia gravis (“MG”).”
> “Receiving RMAT designation offers sponsor companies the benefits of the fast track and breakthrough therapy designation programs, allowing for early, close, and frequent interactions with the FDA with the goal of expediting drug development.”
> “Descartes-08 was previously granted Orphan Drug Designation by the FDA for the treatment of MG.”

Source: [Cartesian Therapeutics RMAT designation press release (2024)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-receives-fda-regenerative-medicine)

<a id="topic-2.1.1-8"></a>

### Special Protocol Assessment agreement on the AURORA design: January 2025

> “FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis (MG).”
> “The SPA agreement indicates that the FDA has determined that the proposed trial design is acceptable to support a future Biologics License Application for Descartes-08 in MG, subject to the ultimate outcome of the trial.”

Source: [Cartesian Therapeutics Special Protocol Assessment press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-fda-special-protocol-assessment)

<a id="topic-2.1.1-9"></a>

### Rare Pediatric Disease Designation for juvenile dermatomyositis: granted September 2024

> “Rare Pediatric Disease Designation for DC-08 in juvenile dermatomyositis granted in September 2024”

Source: [Cartesian Therapeutics corporate presentation, November 2026 (2026)](https://ir.cartesiantherapeutics.com/static-files/6ba3bfe0-f3be-4487-add3-b56dd535e456)

> “Under the FDA’s recently renewed Rare Pediatric Disease Designation and priority review voucher programs, if Descartes-08 is approved for marketing in JDM, Cartesian may qualify for a priority review voucher that can be redeemed to receive priority review of a subsequent marketing application for a different product candidate.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-10"></a>

### AURORA initiation: first participant enrolled May 2025

> “FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG).”

Source: [Cartesian Therapeutics AURORA first participant press release (2025)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-announces-first-participant-enrolled)

<a id="topic-2.1.1-11"></a>

### Development history: phase 1b, phase 2a, and phase 2b portions of MG-001

> “To date, we have completed a Phase 1/2 trial of Descartes-08 in MG, which consisted of a Phase 1b portion, a Phase 2a portion, and a Phase 2b portion.”
> “The results of the Phase 2a portion of the trial, published in the Lancet Neurology in July 2023, indicated that after six weekly infusions of Descartes-08, the average improvement in all disease severity scores was three-to-five-fold greater than what is considered clinically meaningful by expert consensus.”
> “Follow-on results of the Phase 2b portion of the trial were presented in December 2024.”
> “In April, 2025, we reported updated, 12-month data from this trial and published this data in Nature Medicine in January 2026.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-12"></a>

### Clinical exposure across indications through December 2025

> “As of December 31, 2025, we have administered Descartes-08 to over 100 patients suffering from one of MG, multiple myeloma, and other diseases in open-label and randomized placebo-controlled trials on an outpatient basis.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-13"></a>

### Other indications: myositis (TRITON) and pediatric autoimmune diseases (HELIOS)

> “Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continue to progress, with data from both trials expected in 1H27”
> “The randomized, double-blind, placebo-controlled Phase 2 TRITON trial in myositis is designed to assess Descartes-08 versus placebo (1:1 randomization) administered as six weekly outpatient infusions without preconditioning chemotherapy in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome.”
> “Enrollment remains ongoing in the Phase 1/2 HELIOS pediatric trial of Descartes-08 in children and young adults with autoimmune diseases, including JDM.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.1.1-14"></a>

### Systemic lupus erythematosus: development discontinued after November 2025 topline data

> “In November 2025, we announced topline data from our Phase 2 trial in SLE, a chronic autoimmune disease that causes systemic inflammation which affects multiple organ systems.”
> “We also announced a pause in further development of Descartes-08 in SLE, including further enrollment in the Phase 2 trial, in order to prioritize opportunities in MG and myositis.”
> “Shortly thereafter we made a further decision to no longer pursue development of Descartes-08 in SLE.”

Source: [Cartesian Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000064/rnac-20251231.htm)

<a id="topic-2.1.1-15"></a>

### Cash position and runway into 2028, September 2026

> “Cash, cash equivalents and restricted cash as of September 30, 2026 was $124.7 million, inclusive of the initial $50 million tranche of non-dilutive financing from K2 HealthVentures (K2HV) and $22.8 million raised year to date after commissions and expenses through the Company’s at the market offering program.”
> “The Company’s current cash resources on hand are expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial, into 2028.”

Source: [Cartesian Therapeutics third quarter 2026 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-third-quarter-2026-financial)

> “The Company believes the cash, cash equivalents and restricted cash as of September 30, 2026 will enable it to fund its current planned operations for at least the next 12 months from the filing of this Quarterly Report.”
> “As of September 30, 2026, the Company had an accumulated deficit of $857.3 million.”
> “The successful development of product candidates requires substantial working capital, which may not be available to the Company on favorable terms or at all.”

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)

<a id="topic-2.1.1-16"></a>

### Financing: K2 HealthVentures term loan facility and at-the-market program

> “On May 22, 2026, the Company entered into the Loan Agreement (as defined below) with K2HV (as defined below), providing for Term Loan Facility (as defined below) with aggregate commitments of up to $150.0 million available in four tranches, subject to the satisfaction of certain conditions precedent.”
> “As of September 30, 2026, the Company has borrowed $50.0 million under the Loan Agreement.”
> “Beginning on January 1, 2029, the Loan Agreement requires the Company to maintain compliance with a minimum trailing three-month net product revenue covenant of $40.0 million, tested as of the last day of each calendar quarter, with required quarter-over-quarter growth.”
> “As of September 30, 2026, approximately $75.5 million remains available under the at the market program.”

Source: [Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000111/rnac-20260930.htm)

<a id="topic-2.1.1-17"></a>

### Cash runway into mid-2027, March 2026, superseded in May 2026

> “Cash, cash equivalents and restricted cash as of December 31, 2025 was $126.9 million and is expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial and initiation of its Phase 2 TRITON trial in myositis, into mid-2027.”

Source: [Cartesian Therapeutics full year 2025 results (2026)](https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
